Published in Health Business Week, January 19th, 2007
Albuferon is being developed by HGS and Novartis under an exclusive worldwide development and commercialization agreement entered into in June 2006.
"We are pleased to advance Albuferon to phase III clinical trials," said H. Thomas Watkins, president and CEO, HGS. "Hepatitis C is the most common chronic blood-borne infection in the developed world. We believe that Albuferon could...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.